Showing results (581-590 of 5,042) with videos related to

Sort By:
Pageof 505
Multiple Sclerosis and Related Disorders|April 17, 2015
Moyamoya: Another multiple sclerosis mimicFariha Zaheer, Joseph R Berger
Multiple Sclerosis and Related Disorders|April 17, 2015
Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panelJ Theodore Phillips, Michael Hutchinson, Robert Fox, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patientsFrancesca Sangalli, Lucia Moiola, Laura Ferrè, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Pathologic yawning in neuromyelitis optica spectrum disordersMarco A Lana-Peixoto, Dagoberto Callegaro, Natália Talim, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjectsRashid H Bibani, Christopher R Tench, Jithin George, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based studyRuth Ann Marrie, Bo Nancy Yu, Stella Leung, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Persistence of the effects of attention and executive functions intensive rehabilitation in relapsing remitting multiple sclerosisF Mattioli, C Stampatori, C Scarpazza, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypesEvanthia Bernitsas, Fen Bao, Navid Seraji-Bozorgzad, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapseB A Cohen, P K Coyle, T Leist, et al.
Multiple Sclerosis and Related Disorders|March 20, 2015
Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?Debra Fine, Abhishek Dattani, Isabel Moreira, et al.
Pageof 505